Twitter Ola Landgren, M.D. DrOlaLandgren | Ola Landgren, M.D. (@DrOlaLandgren) のツイート

@DrJashDatta⁩ speaking on his pancreas cancer research ⁦@SylvesterCancer⁩ during the second day of our FACCA retre… twitter.com/i/web/status/1…

Join leading #myeloma experts on April 6th at the #Miami Myeloma MRD Meeting 2023! The virtual event is designed sp… twitter.com/i/web/status/1…

6b48fzzd reasonably small
Ola Landgren, M.D.@DrOlaLandgren

Strong science by @AshAlizadeh on precursor lesions —> follicular lymphoma. Results suggest BCL2 lesions are 1st -… twitter.com/i/web/status/1…

6b48fzzd reasonably small
Ola Landgren, M.D.@DrOlaLandgren

@AshAlizadeh @CD_AACR Outstanding work @AshAlizadeh ! Great congrats!

Great intro from @DrGarethMorgan1 on how large data set can be used to generate treatment adjusted individualized p… twitter.com/i/web/status/1…

Awsome talk from Niels about how spatial heterogeneity and even one single cell can lead to disease progression twitter.com/VJHemOnc/statu…

6b48fzzd reasonably small
Ola Landgren, M.D.@DrOlaLandgren

Bortezomib, Lenalidomide, Dexamethasone (VRd) vs Carfilzomib, Lenalidomide, Dexamethasone (KRd) in newly diagnosed… twitter.com/i/web/status/1…

Marta Chesi presenting our collaborative genomic data on VkMYC mice with ⁦@Leif_Bergsagel⁩ David Coffey ⁦… twitter.com/i/web/status/1…

6b48fzzd reasonably small
Ola Landgren, M.D.@DrOlaLandgren

Pfizer buys Seagen for $43 billion. Boosts access to novel cancer drugs and changes dramatically the oncology prese… twitter.com/i/web/status/1…

6b48fzzd reasonably small
Ola Landgren, M.D.@DrOlaLandgren

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patient… twitter.com/i/web/status/1…

An amazing event, with all our MM clinic and research nurses, nurse practitioners, doctors, infusion nurses, and of… twitter.com/i/web/status/1…

6b48fzzd reasonably small
Ola Landgren, M.D.@DrOlaLandgren

VJHemOnc is the official media partner of the workshop.

@theMMRF @IMFmyeloma @HealthtreeMM @SylvesterCancertwitter.com/i/web/status/1…

6b48fzzd reasonably small
Ola Landgren, M.D.@DrOlaLandgren

... meeting is hosted by the Sylvester Comprehensive Cancer Center’s Myeloma Research Institute - in collaboration… twitter.com/i/web/status/1…

6b48fzzd reasonably small
Ola Landgren, M.D.@DrOlaLandgren

... the meeting will feature several opportunities for interactive discussion including Q&A sessions & discussants.… twitter.com/i/web/status/1…

6b48fzzd reasonably small
Ola Landgren, M.D.@DrOlaLandgren

The meeting brings together leading experts in multiple myeloma to discuss the use of minimal residual disease (MRD… twitter.com/i/web/status/1…

6b48fzzd reasonably small
Ola Landgren, M.D.@DrOlaLandgren

Don't miss the 10th annual meeting: "Miami Myeloma MRD 2023 Meeting"!

Date: April 6, 2023 at 9AM to 1PM EST.
Venue… twitter.com/i/web/status/1…

Calling all myeloma patients in S. Florida, caregivers,and those who would like to learn more about the 2nd most co… twitter.com/i/web/status/1…

‼️ The PANGEA Model is out now @TheLancetHaem ‼️

A 🧵on how PANGEA improves prediction accuracy of MGUS & SMM prog… twitter.com/i/web/status/1…

6b48fzzd reasonably small
Ola Landgren, M.D.@DrOlaLandgren

Join for FREE: 10th Annual Miami Myeloma MRD 2023 Meeting on April 6, 2023

World-class speakers, novel methods, re… twitter.com/i/web/status/1…